Y. Karabulut Et Al. , "Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever," RHEUMATOLOGY INTERNATIONAL , vol.42, no.12, pp.2211-2219, 2022
Karabulut, Y. Et Al. 2022. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever. RHEUMATOLOGY INTERNATIONAL , vol.42, no.12 , 2211-2219.
Karabulut, Y., Gezer, H. H., ÖZ, N., Esen, I., & Duruoz, M. T., (2022). Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever. RHEUMATOLOGY INTERNATIONAL , vol.42, no.12, 2211-2219.
Karabulut, Yusuf Et Al. "Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever," RHEUMATOLOGY INTERNATIONAL , vol.42, no.12, 2211-2219, 2022
Karabulut, Yusuf Et Al. "Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever." RHEUMATOLOGY INTERNATIONAL , vol.42, no.12, pp.2211-2219, 2022
Karabulut, Y. Et Al. (2022) . "Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever." RHEUMATOLOGY INTERNATIONAL , vol.42, no.12, pp.2211-2219.
@article{article, author={Yusuf Karabulut Et Al. }, title={Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever}, journal={RHEUMATOLOGY INTERNATIONAL}, year=2022, pages={2211-2219} }